Insightec Exablate Prostate

2021: Platform Launch

In early December 2021, Insightec announced the launch of the Exablate Prostate platform, which uses branded directional sound wave technology to kill prostate cancer tissue in patients at low or medium risk.

The system directs high-intensity focused ultrasound waves to a given tissue, directing them throughout the process with a magnetic resonance imaging (MRI) apparatus that helps navigate the patient's anatomy and monitor the tissue temperature in real time. Exablate Prostate is designed to break down only the target tissue while preserving the surrounding healthy structures. In addition, the acoustic ablation method does not require incisions and can be performed in one session, which reduces the long recovery time that is usually required after more invasive cancer treatments .

Exablate Prostate MRI system for treating prostate cancer with sound waves released

Exablate focused ultrasound demonstrated effective control of locally advanced prostate cancer in individual patients based on the results of a two-year biopsy. Precision ablation combined with magnetic resonance imaging and thermal feedback may allow men to consider applying a tissue-preserving approach and postpone or avoid radical therapy, said Behfar Ehdaie, principal investigator of the study and urologist surgeon at Memorial Sloan Kettering Cancer Center.

In trials sponsored by Insightec, Exablate Prostate has been shown to cause minimal damage to healthy tissue surrounding prostate cancer tissue. The system also did not significantly affect patients' post-surgery potency and their ability to continue sexual activity. Resolution allows the use of a brain-centered version of focused ultrasound technology to treat patients with advanced Parkinson's disease who experience problems with mobility, rigidity and dyskinesia - a complication that causes involuntary muscle movements. Approval from the Food and Drug Administration (FDA) complements other indications for Exablate Neuro use that allow the system to be used to treat tremor in patients with tremor-dominated Parkinson's disease or drug-resistant essential tremor.^[1]

Notes